ArticleFrontiers in immunology2026
Identification and validation of biomarkers related to mismatch repair for prognosis prediction in glioma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gliomas are aggressive brain tumors with a dismal prognosis, and their development, progression, and responsiveness to treatment are all impacted by mismatch repair (MMR) deficiency. This work aimed to construct a predictive risk model based on MMR-related genes and confirm its clinical applicability, with a focus on identifying novel therapeutic targets. Methods: Clinical and mRNA expression data from The Cancer Genome Atlas (TCGA) and The Chinese Glioma Genome Atlas (CGGA) glioma patients were analyzed. MMR-related genes were sourced from the Molecular Signatures Database (MSigDB). A risk score model was created using multivariate Cox regression and LASSO analysis. Patients were categorized into high- and low-risk groups based on the median risk score. The model's performance was assessed using ROC curves, AUC, and Kaplan-Meier survival analysis. Immune cell infiltration was quantified using "CIBERSORT" and "QUANTISEQ". Immunotherapy potential was evaluated via TMB, TME, and TIDE scores. The half maximal inhibitory concentration (IC Results: An eight-MMR-related gene prognostic model (HMGB1, MCM8, MUTYH, PMS1, RNASEH2B, RNASEH2C, RPA3, TP73) was constructed. The risk score was an independent prognostic factor, with high-risk patients showing significantly poorer overall survival. The validity of this model has been validated in the CGGA dataset. Significant differences in immune infiltration, TME, and TMB scores were observed between risk groups. Drug sensitivity analysis revealed distinct IC Conclusion: This study establishes a robust MMR-related prognostic model for glioma that effectively stratifies patients, predicts survival, and reflects distinct immune microenvironments. Critically, we identify MCM8 as a novel and actionable biomarker that modulates TMZ sensitivity, offering a promising avenue for personalized treatment in glioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.